Shares of Natera Inc (NASDAQ:NTRA) have been given an average rating of “Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $29.00.
Several research analysts have recently issued reports on the company. Zacks Investment Research raised Natera from a “sell” rating to a “buy” rating and set a $23.00 price target for the company in a research note on Saturday, October 13th. Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Natera in a research note on Friday, November 9th. BidaskClub raised Natera from a “strong sell” rating to a “sell” rating in a research note on Friday, December 7th. Finally, ValuEngine raised Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 15th.
A number of hedge funds have recently made changes to their positions in NTRA. Pacer Advisors Inc. bought a new position in Natera during the third quarter valued at about $106,000. Point72 Hong Kong Ltd purchased a new stake in shares of Natera during the third quarter valued at $119,000. Quantbot Technologies LP purchased a new stake in shares of Natera during the third quarter valued at $135,000. State Board of Administration of Florida Retirement System lifted its holdings in shares of Natera by 6.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,485 shares of the medical research company’s stock valued at $160,000 after purchasing an additional 717 shares during the last quarter. Finally, Meeder Asset Management Inc. lifted its holdings in shares of Natera by 920.5% during the third quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock valued at $200,000 after purchasing an additional 7,576 shares during the last quarter. 87.85% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ:NTRA traded up $0.41 on Friday, hitting $14.75. The company’s stock had a trading volume of 342,414 shares, compared to its average volume of 521,774. Natera has a 12 month low of $8.60 and a 12 month high of $29.62. The stock has a market cap of $886.55 million, a price-to-earnings ratio of -6.15 and a beta of 1.79. The company has a debt-to-equity ratio of 1.30, a quick ratio of 2.32 and a current ratio of 2.44.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, November 8th. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.03). Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. The business had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. During the same period in the previous year, the company posted ($0.51) EPS. The company’s revenue for the quarter was up 16.8% compared to the same quarter last year. On average, equities research analysts predict that Natera will post -2.12 EPS for the current year.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Article: What are Institutional Investors?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.